MVB Financial Corp. MVBF 深 沪
等待开盘 07-23 09:30:00 美东时间
24.71
+0.030
+0.12%
华盛通- 最 高24.97
- 今 开24.94
- 成交量 3.33万股
- 最 低 24.615
- 昨 收 24.68
- 总市值 3.21亿
- 52周最高 25.125
- 市盈率 静 16.16
- 换手率 0.26%
- 52周最低 15.4154
- 委 比 69.81%
- 总股本 1299.47万
- 历史最高 43.15
- 量 比 0.17
- 振 幅 1.44%
- 历史最低 5.06
- 每 手 1
- 风险率 1.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅687%！ 花旗上调新氧科技目标价升至5.5美元，评级"买入"
今日重点评级关注：B. Riley证券：维持内克塔治疗"买入"评级，目标价从60美元升至85美元；Oppenheimer：维持Praxis Precision Medicine"跑赢大市"评级，目标价从97美元升至115美元
07-09 09:26
Raymond James Reiterates Outperform on MVB Financial, Raises Price Target to $25
Raymond James analyst Daniel Tamayo reiterates MVB Financial (NASDAQ:MVBF) with a Outperform and raises the price target from $20 to $25.
07-09 00:25
MVB Financial declares $0.17 dividend
MVB Financial (NASDAQ:MVBF) declares $0.17/share quarterly dividend, in line with previous. Forward yield 3.53% Payable June 15; for shareholders of record June 1; ex-div May 29. See MVBF Dividend Sc...
05-21 20:35
MVB Financial’s Strategic Focus at Shareholder Meeting
MVB Financial ( ($MVBF) ) has issued an announcement. At the 2025 Annual Meetin...
05-20 21:48
MVB Financial announces stock repurchase program
MVB Financial (NASDAQ:MVBF) authorized a stock repurchase program of up to $10M of its common stock on Monday. MVB intends to begin repurchasing stock in May 2025, and the stock repurchase program wi...
05-19 20:44
MVB Financial Corp. Announces The Authorization Of A Stock Repurchase Program Of Up To $10M Of Common Stock
The Board of Directors of MVB Financial Corp. ("MVBF" or "MVB Financial") (NASDAQ:MVBF) today announced the authorization of a stock repurchase program of up to $10 million of MVB's common stock.MVB intends to begin
05-19 20:37
MVB Financial Reports Strong Q4 2024 Financial Highlights
MVB Financial ( ($MVBF) ) has issued an update. MVB Financial Corp. has reporte...
03-19 04:33
美股大行评级 | 美银证券：维持艾伯维"中性"评级，目标价从200美元升至223美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1103964892578983937.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Syndax制药(SNDX)"超配"评级，目标价从35美元升至39美元</p> <p>• 摩根大通：维持Apellis Pharmaceuticals(APLS)"超配"评级，目标价从50美元升至54美元</
03-05 09:55
美股大行评级 | Piper Sandler：上调ACNB Corp评级至"超配"，目标价从37美元升至50美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1103601922058588161.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 丰业银行：维持Rocket Pharmaceuticals(RCKT)"跑赢大市"评级，目标价从51美元升至52美元</p> <p>• HC Wainwright & Co.：维持Revolution Medici
03-04 08:54
